Abbreviated or Standard Dual Antiplatelet Therapy by Sex in Patients at High Bleeding Risk: A Prespecified Secondary Analysis of a Randomized Clinical Trial
Importance Abbreviated dual antiplatelet therapy (DAPT) reduces bleeding with no increase
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …
in ischemic events in patients at high bleeding risk (HBR) undergoing percutaneous …
[HTML][HTML] Short Versus Long-Term Dual Antiplatelet Therapy in Patients at High Bleeding Risk Undergoing PCI in Contemporary Practice: A Systemic Review and Meta …
N Mankerious, M Megaly, R Hemetsberger… - Cardiology and …, 2023 - Springer
Introduction Patients at high bleeding risk (HBR patients) represent an important subset of
patients undergoing percutaneous coronary intervention (PCI). It remains unclear whether a …
patients undergoing percutaneous coronary intervention (PCI). It remains unclear whether a …
Duration of dual antiplatelet therapy for patients at high bleeding risk undergoing PCI
Background The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …
coronary intervention (PCI) among patients at high bleeding risk (HBR) is unknown …
[HTML][HTML] Short dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk patients: Systematic review and meta-analysis
KR Bainey, G Marquis-Gravel, BJ MacDonald… - Plos one, 2023 - journals.plos.org
Introduction Dual antiplatelet therapy (DAPT) following percutaneous coronary intervention
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …
(PCI) reduces major adverse cardiovascular events (MACE) and stent thrombosis. However …
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk patients: A systematic review and meta …
Background Optimal dual antiplatelet therapy (DAPT) duration in patients at high bleeding
risk (HBR) is not fully defined. We aimed to compare the safety and effectiveness of short …
risk (HBR) is not fully defined. We aimed to compare the safety and effectiveness of short …
Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials
F Costa, C Montalto, M Branca, SJ Hong… - European Heart …, 2023 - academic.oup.com
Aims The optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
intervention (PCI) in patients at high bleeding risk (HBR) is still debated. The current study …
Short dual antiplatelet therapy in patients with high bleeding risk undergoing percutaneous coronary intervention: a systematic review and meta-analysis
J Zhang, Z Chen, C Li, D Wang, S He… - Coronary Artery …, 2022 - journals.lww.com
Background The efficacy and safety of an abbreviated duration of dual antiplatelet therapy
(DAPT) in patients with high bleeding risk (HBR) undergoing percutaneous coronary …
(DAPT) in patients with high bleeding risk (HBR) undergoing percutaneous coronary …
Impact of 6‐versus 12‐month dual antiplatelet therapy on clinical prognosis in patients with high bleeding risk: Insights from the 4‐year results of the I LOVE IT 2 study
J Zhang, M Qiu, K Na, S Ma, Z Jiang… - Catheterization and …, 2021 - Wiley Online Library
Objectives To explore the impact of 6‐versus 12‐month dual antiplatelet therapy (DAPT) on
the clinical prognosis of high bleeding risk (HBR) patients. Background The optimal DAPT …
the clinical prognosis of high bleeding risk (HBR) patients. Background The optimal DAPT …
Racial differences in ischaemia/bleeding risk trade-off during anti-platelet therapy: individual patient level landmark meta-analysis from seven RCTs
J Kang, KW Park, T Palmerini, GW Stone… - Thrombosis and …, 2019 - thieme-connect.com
Background Prolonged dual anti-platelet therapy (DAPT) is intended to reduce ischaemic
events, at the cost of an increased bleeding risk in patients undergoing percutaneous …
events, at the cost of an increased bleeding risk in patients undergoing percutaneous …
Details on the effect of very short dual antiplatelet therapy after drug-eluting stent implantation in patients with high bleeding risk: insight from the STOPDAPT-2 trial
H Watanabe, T Domei, T Morimoto, M Natsuaki… - Cardiovascular …, 2021 - Springer
Previously we briefly reported the effect of 1-month dual antiplatelet therapy (DAPT) for
patients with high bleeding risk (HBR) receiving percutaneous coronary intervention (PCI) in …
patients with high bleeding risk (HBR) receiving percutaneous coronary intervention (PCI) in …